At Asklepios BioPharmaceutical (AskBio), we are making history with every clinical advancement and aspire to turn hope into cures by unraveling new possibilities for genetic medicine. We are headquartered in Research Triangle Park, North Carolina, a thriving biotechnology hub with nearly 600 life science companies, and have additional research and development facilities in Edinburgh, Scotland, and gene therapy manufacturing in San Sebastian, Spain.
Started in 2001, we are on a never-ending quest to advance genetic technology and life-saving gene therapy. We are singularly focused on a goal to erase genetic disease. It is an audacious goal that will not be accomplished by us alone, but it is one to which we have already made significant contributions.
Almost 40 years ago, AskBio’s scientific co-founder, Jude Samulski, PhD, was the first to demonstrate that adeno-associated virus (AAV) could be cloned for therapeutic purposes. His groundbreaking research propelled the most exciting field in medical research today. His work inspires our world-leading gene therapy platform that is bringing new therapeutics to market and resulting in new methods for lowering the cost of delivery.
Our clinical pipeline covers a broad range of genetic diseases targeting central nervous system, muscle, respiratory, and heart tissues. We have a number of research initiatives taking place to expand our pipeline that we believe will impact the future of other important therapeutics.
Our technology and AAV therapeutic assets have been acquired or licensed by leading biopharmaceutical companies such as Pfizer, Takeda, and Novartis (AveXis). This validates our gene therapy development leadership and is even more significant considering that the first two gene therapies approved by the FDA are based on the research of our founders and AskBio’s current technology.